Participant flow.
NSCLC, lung adenocarcinoma
ONCOLOGY, LUNG ADENOCARCINOMA, NSCLC
The key criteria for eligibility were a diagnosis of histologically/cytologically confirmed, locally advanced, or metastatic (stage IIIB–IV) lung adenocarcinoma that had progressed on first-line platinum-based chemotherapy (which included continuation or switch maintenance therapy, one prior adjuvant and/or neoadjuvant chemotherapy line, and prior immunochemotherapy regimens). Other inclusion criteria were age ≥18 years at the date of informed consent, a life expectancy of ≥3 months, and an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 at screening. Patients were excluded if they had received ≥1 line of prior chemotherapy for advanced or metastatic NSCLC, tested positive for activating epidermal growth factor receptor (